Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

Background: We aimed to investigate the potential beneficial effect of immunomodulation therapy on the thromboembolic risk in hospitalized COVID-19 patients. Methods: We searched PubMed and Scopus for randomized trials reporting the outcomes of venous thromboembolism (VTE), ischemic stroke or system...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dimitrios Sagris, Matilda Florentin, Panagiotis Tasoudis, Eleni Korompoki, Nikolaos Gatselis, Evangelos J. Giamarellos-Bourboulis, Haralampos Milionis, James Douketis, Alex C. Spyropoulos, George Dalekos, George Ntaios
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
COVID-19
thromboembolism
tocilizumab
anakinra
hydroxycholoroquine
immunomodulation
Medicine
R
Acceso en línea:https://doaj.org/article/eb0a8112306749678628d0250480b520
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/eb0a8112306749678628d0250480b520

Ejemplares similares